Journal
HAEMATOLOGICA
Volume 102, Issue 8, Pages 1378-1390Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2016.160101
Keywords
-
Categories
Funding
- Austrian Science Fund (FWF) [P24031]
- Osterreichische Krebshilfe Tirol (OKH-KG)
- Austrian Science Fund (FWF) [P 24031] Funding Source: researchfish
- Austrian Science Fund (FWF) [P24031] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
P27(Kip1) (p27) can prevent cell proliferation by inactivating cyclindependent kinases. This function is impaired upon phosphorylation of p27 at tyrosine residue 88. We observed that FLT3 and FLT3-ITD can directly bind and selectively phosphorylate p27 on this residue. Inhibition of FLT3-ITD in cell lines strongly reduced p27 tyrosine 88 phosphorylation and resulted in increased p27 levels and cell cycle arrest. Subsequent analysis revealed the presence of tyrosine 88 phosphorylated p27 in primary patient samples. Inhibition of FLT3 kinase activity with AC220 significantly reduced p27 tyrosine 88 phosphorylation in cells isolated from FLT3 wild type expressing acute myeloid leukemia (AML) patients. In FLT3-ITD positive AML patients, p27 tyrosine 88 phosphorylation was reduced in 5 out of 9 subjects, but, surprisingly, was increased in 4 patients. This indicated that other tyrosine kinases such as Src family kinases might contribute to p27 tyrosine 88 phosphorylation in FLT3-ITD positive AML cells. In fact, incubation with the Src family kinase inhibitor dasatinib could decrease p27 tyrosine 88 phosphorylation in these patient samples, indicating that p27 phosphorylated on tyrosine 88 may be a therapeutic marker for the treatment of AML patients with tyrosine kinase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available